SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02279511

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Evaluating the Effectiveness of the Use of Intravenous Infusions of Adenosine Triphosphate (ATP) in Patients With Moderate Alzheimer's Disease and Severe: Double-blind Dose Finding Clinical Trial.

To Check whether systemic treatment with ATP alters the profile of cerebral metabolism in patients with Alzheimer's disease using MRS techniques (Magnetic Resonance Spectroscopy) and adjust the infusion (minimum effective dose) that promotes this metabolic change.

NCT02279511 Alzheimer's Disease
MeSH:Alzheimer Disease
HPO:Alzheimer disease

2 Interventions

Name: ADENOSINE TRIPHOSPHATE

Description: Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
Type: Drug
Group Labels: 2

24 hours infusion of ATP 6 hours infusion of ATP

Name: PLACEBO

Description: Infusion of 500 mL of saline solution. (IV)
Type: Drug
Group Labels: 2

24 hours infusion of placebo 6 hours infusion of placebo


Primary Outcomes

Description: Spectroscopy will be taken one hour after the infusion (7h for patients allocated to 6h arm and 25h in 24h infusion arm)

Measure: Detection of brain metabolic changes after ATP infusion by spectroscopy techniques (H + MRS)

Time: expected average of 7-25 hours post infusion

Description: one hour after the infusion (7h for patients allocated to 6h arm and 25h in 24h infusion arm)

Measure: Changes in Cogstate results

Time: expected average of 7-25 hours post infusion

Secondary Outcomes

Description: The cogstate is a software used to evaluate cognitive impairment

Measure: Changes in Cogstate results

Time: 3 months compared to baseline.

Measure: Changes in test Mini-Mental State Examination

Time: 3 months compared to baseline.

Measure: Changes in synaptic activity after treatment administration Neurological examination

Time: post treatment or 3 months post baseline

Measure: Electrocardiogram results

Time: an expected average of 90 days

Measure: adverse events

Time: at 90 days

Purpose: Other

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 rs11870474

- 9. The subject or his legal representative give prior informed consent that includes genetic studies of Apolipoprotein E and rs11870474.



HPO Nodes


HPO: